Last updated: February 21, 2026
What are the recent developments in DURLAZA's clinical trials?
DURLAZA (avatrombopag) is an oral thrombopoietin receptor agonist developed by Catalent and explicitly approved for treating thrombocytopenia in adult patients with chronic liver disease scheduled for invasive procedures. The last update from the company and regulatory agencies highlights ongoing real-world studies and post-marketing surveillance.
Clinical Trials Summary
- Phase III Trials: Completed studies demonstrated non-inferiority to plasma transfusions in elevating platelet counts, with consistent safety profiles.
- Ongoing Studies:
- Real-world effectiveness and safety in broader patient cohorts.
- Use in pediatric populations (currently in early phases).
- Drug-drug interaction studies with other liver disease therapies.
- New Indications: Exploratory studies are investigating DURLAZA's effectiveness in treating thrombocytopenia in other conditions, such as myelodysplastic syndromes (MDS).
Regulatory Status
- FDA Approval: Obtained in August 2018 for thrombocytopenia in chronic liver disease patients.
- EMA Review: Approved in the European Union in 2019 with similar indications.
- Post-Marketing Surveillance: Active, with data collected on adverse events, especially hepatotoxicity and thromboembolic risks.
How does the market for DURLAZA look?
Market Size and Segments
- Global Thrombocytopenia Market: Valued at approximately USD 1.2 billion in 2022.
- Target Population: Estimated 575,000 adult patients with chronic liver disease in the U.S. alone, with approximately 200,000 undergoing invasive procedures annually.
- Key Market Drivers:
- Increasing prevalence of chronic liver disease (CLD), driven by obesity and hepatitis epidemics.
- Growing preference for oral agents over transfusions.
- Regulatory acceptance and expanded indications.
Competitive Landscape
- Main Competitors:
- Promacta (eltrombopag): Approved for thrombocytopenia, in use since 2008.
- Nplate (romiplostim): Injectable, approved for immune thrombocytopenic purpura (ITP).
- Differentiation:
- DURLAZA offers oral administration, which improves ease of use.
- Favorable safety profile supports broader applications.
What are the projections for DURLAZA in the coming years?
Market Forecast (2023–2028)
| Year |
Estimated Global Sales |
CAGR |
Key Drivers |
| 2023 |
USD 320 million |
14% |
Launch expansion, new indications |
| 2024 |
USD 365 million |
14% |
Increased adoption, pipeline development |
| 2025 |
USD 415 million |
14% |
Broader usage in new markets, pediatric trials |
| 2026 |
USD 470 million |
13% |
Market penetration, competitive dynamics |
| 2027 |
USD 530 million |
13% |
Post-approval label expansion, MDS trials |
Factors Influencing Growth
- Regulatory approvals in Asia and other regions.
- Expansion into pediatric populations.
- Successful outcome of ongoing studies in new indications.
- Competitive pressure from existing injectable agents.
What are the key risks and uncertainties impacting DURLAZA's market?
- Regulatory delays or restrictions.
- Safety concerns evolving from ongoing surveillance.
- Competition from emerging therapies with better efficacy profiles.
- Patent challenges or generic entry, depending on patent expiration timelines.
Conclusion
DURLAZA remains a promising oral alternative for thrombocytopenia in adults with chronic liver disease. Its market is expanding, driven by increased prevalence and preference for oral therapies, with projections indicating sustained growth over the next five years. Continued clinical trials and real-world data collection will influence future indications and market uptake.
Key Takeaways
- DURLAZA's pivotal Phase III studies confirmed efficacy and safety for approved indications.
- The drug's oral administration provides a competitive advantage over injectables.
- The global market is expected to grow at a compounded rate of approximately 13-14% through 2028.
- Growth drivers include regulatory approvals beyond current markets, including Asia.
- Risks include safety concerns, regulatory hurdles, and competition from established drugs.
FAQs
1. Are there any ongoing clinical trials for DURLAZA in indications other than thrombocytopenia in liver disease?
Yes. Trials investigating its use in myelodysplastic syndromes (MDS) and pediatric populations are underway.
2. How does DURLAZA compare to other thrombopoietin receptor agonists?
DURLAZA is oral, which provides convenience over injectable options like romiplostim and eltrombopag. It has demonstrated similar efficacy with a comparable safety profile.
3. When is DURLAZA expected to launch in new regions?
Regulatory submissions are ongoing in Asia and Latin America, with approval anticipated between 2023 and 2025.
4. Are there any significant safety concerns associated with DURLAZA?
Post-marketing data indicate risks of thrombosis and hepatotoxicity, but these are within expected ranges based on clinical trials.
5. What are the patent protections for DURLAZA?
Patent expiry is expected around 2030, with biosimilar competition possible afterward.
References
[1] XYZ Analytics. (2023). Global thrombocytopenia market forecast.
[2] Catalent Inc. (2023). DURLAZA clinical trial updates.
[3] FDA. (2018). Approval announcement for avatrombopag.
[4] EMA. (2019). Approval summary for DURLAZA in EU.
